融創中國(1918.HK)半日收漲4.17% 連續兩個月銷售額實現兩位數環比增長
格隆匯7月6日丨融創中國(1918.HK)半日收漲4.17%報39.95港元,股價創今年3月以來新高,半日成交8.83億港元,最新總市值1861億港元。該股近3日累漲23%。融創中國最新公佈的6月銷售業績公告顯示,上半年累計實現合同銷售金額1952.7億元;公司5月銷售按月增長33.2%,6月銷售按月增長20.78%,連續兩個月均實現了銷售業績環比兩位數增長的好成績。分析人士稱,根據融創中國以往的銷售週期來看,下半年才是集團銷售旺季。第二季度銷售業績回暖足以顯示,融創已逐步擺脱年初外部環境的影響,重回正軌,下半年的銷售將迎來新高峯。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.